What is a stock summary page? Click here for an overview.
Business Description
Cidara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1717571079
Description
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 53.08 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.83 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -78 | |||||
| 3-Year EBITDA Growth Rate | -19.8 | |||||
| 3-Year EPS without NRI Growth Rate | -18.3 | |||||
| 3-Year FCF Growth Rate | -42.4 | |||||
| 3-Year Book Growth Rate | 32.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.58 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.78 | |||||
| 9-Day RSI | 44.2 | |||||
| 14-Day RSI | 46.16 | |||||
| 3-1 Month Momentum % | -7.37 | |||||
| 6-1 Month Momentum % | 131.63 | |||||
| 12-1 Month Momentum % | 35.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | |||||
| Quick Ratio | 4.25 | |||||
| Cash Ratio | 3.83 | |||||
| Days Inventory | 1232.47 | |||||
| Days Sales Outstanding | 225.69 | |||||
| Days Payable | 826.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -47.8 | |||||
| Shareholder Yield % | -137.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.17 | |||||
| Operating Margin % | -1065.24 | |||||
| Net Margin % | -1937.56 | |||||
| FCF Margin % | -2015.54 | |||||
| ROE % | -221.2 | |||||
| ROA % | -126.69 | |||||
| ROIC % | -434.27 | |||||
| 3-Year ROIIC % | 861.69 | |||||
| ROC (Joel Greenblatt) % | -2032.57 | |||||
| ROCE % | -115.6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.82 | |||||
| PB Ratio | 1.27 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| EV-to-EBIT | -0.53 | |||||
| EV-to-EBITDA | -0.53 | |||||
| EV-to-Revenue | 5.61 | |||||
| EV-to-Forward-Revenue | 2.19 | |||||
| EV-to-FCF | -0.33 | |||||
| Price-to-GF-Value | 7.33 | |||||
| Price-to-Net-Current-Asset-Value | 1.3 | |||||
| Price-to-Net-Cash | 1.5 | |||||
| Earnings Yield (Greenblatt) % | -188.68 | |||||
| FCF Yield % | -85.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CDTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cidara Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.765 | ||
| EPS (TTM) ($) | -30.09 | ||
| Beta | 1.11 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.08 | ||
| Volatility % | 94.67 | ||
| 14-Day RSI | 46.16 | ||
| 14-Day ATR ($) | 1.659979 | ||
| 20-Day SMA ($) | 22.501 | ||
| 12-1 Month Momentum % | 35.33 | ||
| 52-Week Range ($) | 10.004 - 28.42 | ||
| Shares Outstanding (Mil) | 10.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cidara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cidara Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cidara Therapeutics Inc Frequently Asked Questions
What is Cidara Therapeutics Inc(CDTX)'s stock price today?
The current price of CDTX is $18.92. The 52 week high of CDTX is $28.42 and 52 week low is $10.00.
When is next earnings date of Cidara Therapeutics Inc(CDTX)?
The next earnings date of Cidara Therapeutics Inc(CDTX) is 2025-04-22 Est..
Does Cidara Therapeutics Inc(CDTX) pay dividends? If so, how much?
Cidara Therapeutics Inc(CDTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers